Menstrual Cycle Irregularity as a Cardiovascular Early Warning Sign

Women with irregular menstrual cycles face a 19% increased risk of cardiovascular disease, according to UK Biobank data tracking 58,056 women over 11.8 years. The 2025 AHA guidelines now formally designate PCOS, endometriosis, and cycle irregularity as cardiovascular risk-enhancing factors. Short cycles under 21 days carry a 29% elevated risk. Long cycles beyond 35 days carry 11% elevated risk. Your period is a vital sign your cardiologist should be reading.

Her gynecologist said “irregular periods are common, don’t worry about it.” Her cardiologist, reading the same history, said: irregular periods in a woman under 40 are a cardiovascular risk conversation.

I see this disconnect weekly. A 34-year-old woman sits in my exam room with chest tightness during exercise. Her primary care records show five years of documented cycle irregularity. Nobody connected the dots. Her gynecologist treated the symptom with oral contraceptives. Her internist never asked about her periods. By the time she reached cardiology, her coronary calcium score was 47, placing her above the 90th percentile for her age.

This is not a failure of individual physicians. This is a failure of medical education that taught generations of doctors to silo the reproductive system from the cardiovascular system. That silo kills women.

The Menstrual Cycle as Cardiovascular Vital Sign

The American Heart Association’s 2011 guidelines for cardiovascular disease prevention in women first acknowledged this connection. Mosca et al. designated early menarche before age 12 and irregular menses as risk-enhancing factors. The 2025 update expanded the list to include PCOS, endometriosis, premature menopause before age 40, and hypertensive disorders of pregnancy. 5 / Solid

The clinical logic is straightforward. The menstrual cycle requires precise coordination between the hypothalamus, pituitary, ovaries, and uterus. Disruption at any point signals systemic dysfunction. That dysfunction rarely confines itself to reproduction.

The UK Biobank study, Zhang et al. 2023, followed 58,056 women for a median of 11.8 years. Women reporting any irregular cycles faced a hazard ratio of 1.19 for composite cardiovascular events including coronary heart disease, myocardial infarction, atrial fibrillation, stroke, and heart failure. The 95% confidence interval ranged from 1.08 to 1.31. This was not a subtle signal buried in statistical noise.

Cycle length mattered independently. Short cycles under approximately 22 days carried a hazard ratio of 1.29. Long cycles beyond 35 days carried a hazard ratio of 1.11. The relationship followed a U-shaped curve. Either extreme predicted elevated risk. 5 / Solid

Huang et al. 2020 in the BMJ tracked menstrual regularity across the entire reproductive lifespan. Women with persistently irregular cycles from ages 18 to 22 through ages 40 to 50 faced the highest cardiovascular mortality. The risk accumulated. Each decade of irregularity added to the cumulative vascular burden.

Your period is not a reproductive event. Your period is a cardiovascular report card delivered monthly for four decades. Most physicians throw it away unread.

The PCOS Metabolic Bomb

Polycystic ovary syndrome affects approximately 10% of reproductive-age women. Its hallmark is cycle irregularity, often manifesting as cycles longer than 35 days or fewer than eight cycles per year. Most women with PCOS focus on fertility implications. The cardiovascular implications are more dangerous and arrive earlier.

PCOS carries a 2.0-fold increased risk of type 2 diabetes, per Moran et al. 2010 in Human Reproduction Update. It carries a 1.4-fold increased risk of myocardial infarction, per Manrique-Acevedo et al. 2020 in the Journal of Clinical Endocrinology and Metabolism. It carries a 1.5-fold overall cardiovascular disease risk, per de Groot et al. 2019 in the Journal of the American College of Cardiology. 5 / Solid

The mechanism is insulin resistance.

Approximately 70% of women with PCOS demonstrate insulin resistance independent of body weight. Insulin resistance drives hyperandrogenism. Hyperandrogenism suppresses ovulation. Anovulation produces the irregular cycles. But insulin resistance simultaneously drives endothelial dysfunction, the earliest measurable stage of atherosclerosis.

Meyer et al. 2005 measured flow-mediated dilation in women with PCOS compared to age-matched controls. FMD assesses endothelial function by measuring how much an artery dilates in response to increased blood flow. Healthy young women show FMD of 8-12%. Women with PCOS showed deficits of 3-5% compared to controls. Their arteries had already lost compliance. Their endothelium was already inflamed. Their cardiovascular aging clock was running fast.

This is not a finding that appears at age 50. This is measurable at age 25. By the time a woman with unmanaged PCOS reaches traditional screening age, she has accumulated two decades of accelerated vascular damage.

I call this the Hormonal Vascular Clock framework. Every month of abnormal cycling is a month of abnormal vascular stress. The damage compounds silently until it becomes symptomatic, and symptomatic cardiovascular disease in women often presents as sudden death.

Women don’t die from what they have. Women die from what they hold.

The Hypothalamic Amenorrhea Paradox

Functional hypothalamic amenorrhea presents a different mechanism but similar cardiovascular endpoint. FHA occurs when the hypothalamus suppresses gonadotropin-releasing hormone pulsatility. Without GnRH pulses, the pituitary cannot release adequate follicle-stimulating hormone or luteinizing hormone. Without FSH and LH, the ovaries cannot produce estrogen or trigger ovulation.

The result is estradiol levels below 50 pg/mL, per the diagnostic criteria established by Gordon et al. 2017 in the Endocrine Society guidelines. For context, premenopausal women typically cycle between 30 pg/mL in the early follicular phase and 200-400 pg/mL at ovulation. FHA produces sustained levels characteristic of menopause in a 25-year-old body.

The cardiovascular implications mirror early menopause. O’Donnell et al. 2001 in the Journal of the American College of Cardiology demonstrated that young women with hypoestrogenic amenorrhea showed 4-6% reductions in brachial artery flow-mediated dilation compared to eumenorrheic controls. Their vessels had lost estrogen-mediated protection. Their cardiovascular risk trajectory had shifted toward that of a postmenopausal woman. 4 / Promising

FHA commonly results from three triggers: excessive exercise, inadequate caloric intake, or psychological stress. The triad appears frequently in elite athletes, women with eating disorders, and high-achieving professionals who sacrifice sleep and meals for performance. These women often appear healthy. They are thin. They exercise. They do not smoke. Traditional risk calculators assign them low cardiovascular risk.

The traditional risk calculators are wrong.

Drinkwater et al. 1984 in the New England Journal of Medicine documented bone loss of 2-3% annually in amenorrheic athletes. Bone loss tracks estrogen deficiency. The same estrogen deficiency that weakens bone also stiffens arteries, promotes endothelial inflammation, and shifts lipid profiles toward atherosclerosis.

A woman who stops menstruating due to overtraining or caloric restriction is not demonstrating discipline. She is demonstrating cardiovascular harm accumulating in real time.

Severe Dysmenorrhea: The Inflammation Signal

Painful periods are common. Disabling periods warrant investigation beyond pain management.

Severe dysmenorrhea frequently signals endometriosis, a condition affecting approximately 10% of reproductive-age women. Endometriosis involves ectopic endometrial tissue that responds to hormonal cycling with inflammation, adhesion formation, and chronic pain. Most gynecological attention focuses on fertility preservation and pain control. The cardiovascular implications receive less attention.

Mu et al. 2016 in Circulation: Cardiovascular Quality and Outcomes analyzed the Nurses’ Health Study II cohort. Women with laparoscopically confirmed endometriosis faced a 2.5-fold increased risk of coronary heart disease. The relative risk of myocardial infarction was 1.52. The relative risk of angina requiring coronary intervention was 1.91. These elevations persisted after adjustment for smoking, body mass index, hypertension, and diabetes. 5 / Solid

The mechanism is systemic inflammation.

Endometriosis produces elevated C-reactive protein, interleukin-6, and tumor necrosis factor alpha. These inflammatory mediators do not remain confined to the pelvis. They circulate. They activate endothelial inflammation throughout the vascular tree. They promote atherosclerotic plaque formation. They destabilize existing plaque.

The same inflammatory burden that causes pelvic pain causes coronary artery damage. The woman presenting with severe dysmenorrhea is simultaneously presenting with elevated cardiovascular risk. The gynecologist prescribing NSAIDs is treating the symptom while the underlying inflammatory process continues damaging coronary arteries.

This is not to criticize pain management. Pain matters. But pain management without cardiovascular risk stratification is incomplete care.

The Risk Enhancement Framework

The 2025 AHA guidelines introduced the concept of risk-enhancing factors. Traditional risk calculators like the Pooled Cohort Equations estimate 10-year atherosclerotic cardiovascular disease risk based on age, sex, race, cholesterol, blood pressure, diabetes status, and smoking. These calculators systematically underestimate risk in women, particularly young women with reproductive health conditions.

Risk-enhancing factors allow clinicians to reclassify borderline-risk patients upward when specific conditions apply. The reproductive health risk enhancers now formally include: polycystic ovary syndrome, endometriosis, premature ovarian insufficiency or menopause before age 40, hypertensive disorders of pregnancy including preeclampsia, and gestational diabetes.

Cycle irregularity falls within the PCOS designation but warrants attention even in women who do not meet full PCOS diagnostic criteria. The Rotterdam criteria for PCOS require two of three features: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. A woman with irregular cycles and no other Rotterdam features still demonstrates hypothalamic-pituitary-ovarian axis dysfunction. She still carries elevated risk.

de Kat et al. 2018 in the Journal of Clinical Endocrinology and Metabolism conducted a systematic review and meta-analysis of reproductive health characteristics and cardiovascular risk. They found that menstrual cycle characteristics in early adulthood predicted cardiovascular events decades later. The signal was present before traditional risk factors emerged.

This is the Hormonal Vascular Clock in action. The reproductive system provides early warning. The cardiovascular system reveals the consequences years later.

What Your Doctor Should Ask

When you sit in a cardiology office, we ask about chest pain, shortness of breath, family history of heart attacks, smoking, diabetes, and cholesterol. We should also ask: How regular are your periods? How long are your cycles? Have you ever been diagnosed with PCOS, endometriosis, or premature menopause? Did you have preeclampsia or gestational diabetes during any pregnancy?

Most cardiologists do not ask these questions. Most electronic health record templates do not prompt for this history. The information exists in gynecology notes that cardiologists rarely access. The silo persists.

Nappi and Cagnacci 2019 in Cardiology Clinics argued that menstrual disorders represent an overlooked window into women’s vascular risk. They proposed routine cardiovascular screening for women presenting with any menstrual abnormality. The proposal remains aspirational rather than standard practice.

You cannot wait for medicine to catch up. You must bring your reproductive history to your cardiovascular care.

Print your menstrual history. Note the age of menarche. Note typical cycle length. Note years of irregularity. Note any diagnosis of PCOS, endometriosis, or premature menopause. Note any hypertensive pregnancy or gestational diabetes. Hand this document to your primary care physician and request cardiovascular risk assessment that incorporates these factors.

The tests to request specifically: fasting glucose, hemoglobin A1c, lipid panel including ApoB, high-sensitivity C-reactive protein, and lipoprotein(a). These tests capture metabolic dysfunction, inflammation, and inherited lipid abnormalities that correlate with reproductive health conditions. A standard lipid panel alone is insufficient.

If you are under 40 with documented cycle irregularity and any additional risk factor, request a coronary artery calcium score. The American College of Cardiology considers CAC scoring reasonable for intermediate-risk patients. Women with reproductive risk enhancers frequently fall into this category even when traditional calculators classify them as low risk.

The Clinical Reality

I recently saw a 38-year-old woman referred for palpitations. Her traditional risk score calculated 2.4% 10-year ASCVD risk. Low. Reassurance seemed appropriate.

Her history revealed a different picture. Menarche at age 10. Irregular cycles since adolescence, eventually diagnosed as PCOS at 26. Gestational diabetes at 32. Cycles averaging 45 days currently.

I ordered a coronary artery calcium score. It returned at 34. This placed her above the 90th percentile for her age and sex. She had subclinical coronary atherosclerosis at 38. Her traditional risk calculator had missed it entirely.

We started a statin. We optimized her metabolic parameters. We discussed lifestyle modifications targeting insulin sensitivity. We repeated the calcium score three years later. It had progressed to 52, but the rate of progression was slower than expected. We had intervened before her first cardiovascular event.

This is what cardiovascular prevention should look like for women with reproductive risk factors. Early recognition. Aggressive screening. Targeted intervention. The menstrual cycle provided the early warning. The CAC score confirmed the vascular damage. Treatment began before symptoms emerged.

Your irregular period is not a nuisance. Your irregular period is a cardiac risk factor hiding in plain sight.

At your next appointment, bring your menstrual history. Request metabolic screening including fasting glucose, A1c, and ApoB. If you have any reproductive risk factor and you are over 35, request a coronary artery calcium score. Print this article and hand it to your physician if they question why cycle history matters to cardiovascular care. The evidence supports you. The guidelines support you. Your heart needs you to advocate.

Frequently Asked Questions

Can irregular periods actually cause heart disease?

Irregular periods do not directly cause heart disease. They serve as a biological signal indicating underlying metabolic or inflammatory conditions that independently damage blood vessels over time. Polycystic ovary syndrome, the most common cause of irregular cycles, produces insulin resistance measurable in peripheral tissues years before glucose intolerance appears on standard blood tests. Endometriosis produces chronic systemic inflammation measurable by elevated C-reactive protein and interleukin-6. Hypothalamic amenorrhea produces estrogen deficiency comparable to menopause in women decades younger than menopause age. Each underlying condition carries its own vascular mechanism. The cycle irregularity is the warning light on your dashboard, not the engine problem itself. Treating only the symptom with oral contraceptives suppresses the warning without addressing the underlying vascular risk.

Should I see a cardiologist if my periods are irregular?

Direct cardiologist referral is not necessary for everyone with cycle irregularity. The appropriate first step is thorough metabolic and cardiovascular screening at your primary care visit. Request fasting glucose, hemoglobin A1c, complete lipid panel with ApoB, high-sensitivity C-reactive protein, and blood pressure measurement. If results reveal elevated fasting glucose above 100 mg/dL, ApoB above 90 mg/dL, hs-CRP above 2 mg/L, or blood pressure above 130/80, cardiologist referral becomes reasonable. If you are over 35 with cycle irregularity and any additional risk factor including family history of premature heart disease, elevated BMI, or smoking history, request a coronary artery calcium score. A score above zero at any age warrants cardiology consultation for primary prevention planning.

Does birth control that stops periods increase heart risk?

Hormonal contraception that suppresses menstruation does not carry the same cardiovascular warning signal as spontaneous cycle irregularity. The distinction is cause versus effect. Spontaneous irregularity reflects hypothalamic, pituitary, ovarian, or uterine dysfunction with systemic metabolic or inflammatory implications. Hormonally induced amenorrhea reflects pharmaceutical suppression of a potentially normal underlying system. However, certain hormonal contraceptives carry their own cardiovascular considerations. Combined oral contraceptives containing both estrogen and progestin increase venous thromboembolism risk 3 to 4-fold. This risk escalates substantially in women who smoke, particularly over age 35. Progestin-only contraceptives carry lower thrombotic risk. Discuss your specific contraceptive choice and cardiovascular risk profile with your prescribing physician.

What cycle length should concern me about heart health?

The UK Biobank analysis of 58,056 women established clear parameters. Cycles consistently shorter than 21 days carried a 29% higher cardiovascular disease risk compared to cycles of 22 to 34 days. Cycles consistently longer than 35 days carried an 11% higher risk. The reference range of 22 to 34 days represents the lowest-risk category. Additionally, cycle variability matters independently of average length. Variability exceeding 7 days between consecutive cycles signals hypothalamic-pituitary dysfunction even when average cycle length falls within normal range. Track your cycles for six months using any period-tracking application. If your average falls outside 22 to 34 days or your variability exceeds 7 days, bring this data to your physician and request metabolic cardiovascular screening.

My doctor says irregular periods are normal. Is that true?

Your doctor is conflating common with normal, two clinically distinct concepts. Irregular cycles affect 14 to 25% of reproductive-age women depending on the definition used and the population studied. This prevalence makes them common. However, population-level data consistently demonstrates that irregular cycles correlate with insulin resistance, chronic inflammation, and measurable endothelial dysfunction. The UK Biobank showed 19% higher cardiovascular event rates. The Nurses’ Health Study showed elevated coronary heart disease risk in women with PCOS. The WISE study demonstrated impaired flow-mediated dilation in young women with cycle irregularity. Common does not mean physiologically benign. When your doctor says irregular periods are normal, respond with: common and normal are different, and I would like cardiovascular screening based on the 2025 AHA guideline recognition of menstrual irregularity as a risk-enhancing factor.